Get the Daily Brief
Latest Biotech News
Evo 2: AI models whole genomes — Nature publishes foundation-model claims
Teams publishing in Nature unveiled Evo 2, a DNA foundation model trained on genomic data from over 100,000 species that the authors say can both interpret and generate long-form genomic sequences...
GLP‑1s linked to lower addiction risk and mapped to addiction biology
Two independent studies connected GLP‑1 receptor agonists—drugs developed for diabetes and obesity—with reduced substance-use harms and with mechanistic actions in addiction biology. A large...
Fragmentomics hits liver disease: cfDNA tests flag fibrosis and cirrhosis
Johns Hopkins researchers and collaborators published pilot data showing cell-free DNA fragmentation patterns—the fragmentome—can identify liver disease states including fibrosis and cirrhosis...
UCLA engineers CAR‑T to breach solid tumor defenses
UCLA scientists presented a next-generation CAR‑T cell platform engineered to overcome the immunosuppressive microenvironment characteristic of many solid tumors. The group described modifications...
Moderna settles LNP dispute: up to $2.25 billion resolves long-running patents
Moderna agreed to a settlement with Genevant Sciences and Arbutus Biopharma that could total up to $2.25 billion to resolve patent claims over lipid nanoparticle (LNP) delivery technology used in...
UCB licenses Antengene TCE: $1.1B deal enters autoimmune T‑cell engager race
UCB SA licensed global rights to Antengene’s preclinical CD19×CD3 bispecific T‑cell engager ATG‑201 in a transaction valued at up to $1.1 billion. Antengene will complete initial Phase 1 studies...
Theravance halves staff, ends R&D after Phase 3 failure
Theravance Biopharma announced a major corporate restructuring after its norepinephrine reuptake inhibitor ampreloxetine failed a Phase 3 study in symptomatic neurogenic orthostatic hypotension...
ARPA‑H funds lymphatic repair: Rice and Georgia Tech win multimillion grants
Two ARPA‑H awards advanced regenerative efforts for lymphatic disease. A Rice University team led by Omid Veiseh secured up to $18.2 million to develop the first regenerative therapy for...
Big pharma and academic AI pacts: Merck–Tempus and Vanderbilt–Bertis tie up
Merck expanded a multi‑year collaboration with Tempus to apply Tempus’ de‑identified clinical and molecular datasets and AI tooling to discover precision oncology biomarkers and mechanisms of...
Moderna pays $950M upfront — ends long LNP patent fight
Moderna agreed to a multi‑hundred‑million dollar settlement with Arbutus Biopharma and Roivant/Genevant to resolve long‑running patent litigation over lipid nanoparticle (LNP) delivery technology....
FDA escalates crackdown: 30+ warning letters target compounded GLP‑1s
The U.S. Food and Drug Administration issued more than 30 warning letters to telehealth and compounding firms for marketing compounded GLP‑1 copycats as comparable to approved products, signaling...
UCB bets $1.1B on Antengene’s CD19xCD3 TCE — enters TCE arena
UCB SA struck a licensing agreement with Antengene for ATG‑201, a CD19/CD3 bispecific T‑cell engager (TCE) aimed at autoimmune indications, in a deal valued at up to $1.1 billion plus near‑term...
Theravance slashes R&D — halts pipeline after late‑stage failure
Theravance Biopharma announced a sweeping restructuring after its norepinephrine reuptake inhibitor ampreloxetine failed a Phase III study in multiple system atrophy and symptomatic neurogenic...
Prime to test FDA flexibility — seeks approval on a two‑patient gene edit
Prime Medicine reversed an earlier decision to shelve PM359 and said it will pursue FDA approval for the prime‑editing therapy for chronic granulomatous disease (CGD) using data from just two...
Liquid biopsy moves beyond cancer — cfDNA fragmentomics IDs liver disease
Researchers from Johns Hopkins, Delfi Diagnostics and collaborators demonstrated that cfDNA fragmentomics can detect liver diseases such as cirrhosis and fibrosis from plasma samples, extending...
AGBT signals a high‑throughput shakeup — sequencing and spatial updates
The Advances in Genome Biology and Technology meeting revealed incremental but important advances across sequencing and spatial biology that together could reshape clinical and discovery...
ARPA‑H awards $21.8M — funds Georgia Tech lymphatic disease therapeutic effort
The Advanced Research Projects Agency for Health (ARPA‑H) awarded up to $21.8 million to Georgia Tech to develop a first‑of‑its‑kind therapeutic intervention for lymphatic diseases. The program...
Stanford debuts iISM — label‑free microscope shows live cells at 120‑nm resolution
Stanford researchers introduced interferometric Image Scanning Microscopy (iISM), a label‑free imaging technique that combines interferometry and image‑scanning methods to visualize live cellular...
Roche commits $480M to South Korea — builds a global clinical‑trial ecosystem
Roche announced a $480 million commitment to expand South Korea’s biopharma infrastructure and attract global clinical trials, aiming to position the country as a major trial hub. The investment...
Evo 2 DNA model: AI designs genomes across the tree of life
A DNA foundation model called Evo 2 was published in Nature and can identify patterns across the genomes of more than 100,000 species and design long genomic sequences. The model accurately flags...